Physician profile
Michael D Stadler
NPI 1184849416
$1,774.70
in general payments reported to CMS, 2019-2025
24 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $217 · 2021: $391 · 2022: $304 · 2023: $225 · 2024: $191 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.98 | 2019-2025 | Lo Loestrin Fe |
| Pfizer INC. | $172.35 | 2019-2024 | |
| Astellas Pharma US INC | $171.91 | 2021-2025 | Veozah, Myrbetriq |
| Organon LLC | $159.21 | 2021-2025 | Nexplanon |
| Ethicon US, LLC | $86.95 | 2020 | |
| Merck Sharp & Dohme LLC | $86.40 | 2020-2021 | |
| Exeltis, USA INC. | $78.02 | 2021-2023 | Slynd |
| Mylan Pharmaceuticals INC. | $74.06 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $60.27 | 2023-2024 | |
| Aspira Women'S Health INC | $60.07 | 2021-2022 | |
| Hologic Sales and Service, LLC | $58.85 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $53.06 | 2019-2020 | |
| Agile Therapeutics, INC. | $41.94 | 2021-2022 | |
| Duchesnay USA Incorporated | $39.78 | 2019 | |
| Amag Pharmaceuticals, INC. | $37.60 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $37.08 | 2021-2025 | Paragard T 380a |
| Avanos Medical | $34.33 | 2019-2021 | |
| Avion Pharmaceuticals | $33.56 | 2021-2023 | Balcoltra |
| Shield Therapeutics INC | $31.92 | 2023-2024 | Accrufer |
| Roche Diagnostics Corporation | $24.16 | 2019 | |
| Lupin INC. | $18.68 | 2019 | |
| Biogen, INC. | $15.52 | 2024 | |
| Allergan, INC. | $14.49 | 2019 | |
| Therapeuticsmd, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.